What Dimenhydrinat Actavis Treats: Main Uses and Benefits

Dimenhydrinat Actavis is commonly used for managing symptoms related to temporary physiological imbalance, specifically focusing on motion-related distress. This medicine is applied in situations involving specific distressing symptoms and is commonly used for the management, including prevention, of symptoms caused by motion sickness, vertigo, and other vestibular disturbances.

---

Therapeutic Focus and Symptom Relief

This medicine is relevant when supportive symptom management is appropriate for kinetosis. It is relevant for managing symptom clusters that may appear suddenly during travel by car, air, or sea, or during other activities involving movement. It contributes to improved comfort during periods of heightened symptoms, supporting patients during episodes of heightened discomfort.

Applied across domains where additional symptomatic support is needed, the medication is commonly used to help with nausea and vomiting that are a result of these balance disturbances. This supportive relief is relevant when symptoms become temporarily overwhelming, and assists with managing the overall symptom load of distressing gastrointestinal manifestations. It may be part of symptomatic management for symptoms like dizziness, assisting with maintaining functional stability.

Quick Fact: Symptomatic Support for Motion Discomfort
Primary Use: Symptomatic relief for kinetosis.
Target Symptoms: Nausea, vomiting, and dizziness (vertigo).
Context: Travel and vestibular instability.

Regulatory References

1. NIH MedlinePlus Drug Information

Population Eligibility for Dimenhydrinat Actavis

The eligibility for using Dimenhydrinat Actavis is strictly defined by regulatory documents based on age, physiological status, and pre-existing medical conditions.

---

Contraindications and Restrictions

Population Status	Regulatory Status
Absolute Contraindications	Use is strictly forbidden for individuals with known hypersensitivity to dimenhydrinate or diphenhydramine, and generally for neonates and premature infants.
Restricted Use	Consult a health professional before use if you have glaucoma, certain breathing problems (e.g., chronic bronchitis), difficulty in urination (e.g., due to prostate enlargement), or seizure disorders.
Physiological Status	Use is not recommended for breastfeeding mothers, as the medicine passes into breast milk. Pregnant women should consult a doctor before use.

---

Age-Based Eligibility

• The medicine is approved for use in adults and children 12 years of age and older, and in children aged 2 to under 12 years under standard labeled conditions.
• Use in children under 2 years of age is restricted and should only occur under the specific direction of a clinician.
• Older adults (geriatric population) should use Dimenhydrinat Actavis with caution due to potential increased sensitivity to its effects, as noted in professional labeling.

Dimenhydrinat Actavis Interactions with other medicines and products

Interactions with Dimenhydrinat Actavis are primarily pharmacodynamic, meaning they result from additive or reinforcing effects in the body, as documented in official regulatory labeling.

---

Documented Interaction Patterns

The most significant interactions involve the additive effects of the medicine's antihistamine and anticholinergic properties.

• Additive Central Nervous System (CNS) Depression: Concomitant use with other CNS depressants can significantly increase sedation and drowsiness. Products cited in official sources include alcohol, hypnotics, sedatives, tranquilizers, and opioid analgesics.
• Intensification of Anticholinergic Effects: Other substances with anticholinergic properties, such as certain antidepressants and other antihistamines, can prolong and intensify adverse effects like urinary retention or dry mouth.

---

Formal Prohibitions and Restrictions

Official regulatory information identifies specific combinations that are prohibited or require extreme caution:

Classification	Interacting Agents
Formally Prohibited	Monoamine Oxidase Inhibitors (MAOIs), Sodium Oxybate
Procedural Risk	Ototoxic drugs (e.g., Aminoglycoside Antibiotics)

Regulatory documents state that Dimenhydrinat Actavis can mask the warning signs of ototoxicity caused by aminoglycoside antibiotics, which may allow irreversible ear damage to progress unnoticed. Additionally, the official labeling notes that elderly patients (65 years and older) may be more susceptible to the severe effects of pharmacodynamic interactions.

Dimenhydrinat Actavis is a salt composed of two moieties: diphenhydramine and 8-chlorotheophylline. The primary pharmacodynamic action is mediated by diphenhydramine, a first-generation histamine H1 receptor inverse agonist and a competitive antagonist at central and peripheral muscarinic acetylcholine receptors ( M1- M5).

The inverse agonism at H1 receptors, particularly within the vestibular system and the chemoreceptor trigger zone (CTZ) in the brainstem, prevents the constitutive activity of the receptor and blocks the binding of the endogenous agonist, histamine. This action decreases the excitability of the vestibular nuclei. The compound also exhibits significant antagonism at muscarinic acetylcholine receptors, which further reduces cholinergic signaling within the reticular formation and the aforementioned vestibular nuclei. Downstream, this dual-receptor modulation modifies signal transduction to the vomiting center in the medulla, resulting in decreased efferent output. The second moiety, 8-chlorotheophylline, acts as an antagonist at adenosine receptors ( A1 and A2), providing a generalized central nervous system (CNS) stimulation that partially counters the sedative effects resulting from central H1 receptor blockade.

This section details the administration guidelines for Dimenhydrinat (Dimenhydrinate). Dimenhydrinat Actavis is available in multiple dosage forms and routes, including Oral (tablets, liquid), Intramuscular (IM), Intravenous (IV), and Rectal (suppositories).

Administration Scope

Field	Guidelines
Route of Administration	Oral, Intramuscular, Intravenous, Rectal.
Timing in Relation to Meals	Oral tablets may be taken with or without food.
Prophylactic Timing	For prevention, the first dose should be taken 30 minutes to 1 hour before the start of the activity.

---

Dosing and Frequency

Age Group	Standard Dose (Per Dose)	Maximum Daily Limit
Adults & Adolescents (ge 12 years)	50 mg to 100 mg	400 mg in 24 hours
Children 6 to 12 years	25 mg to 50 mg	150 mg in 24 hours
Children 2 to under 6 years	12.5 mg to 25 mg	75 mg in 24 hours

Oral doses should be administered every 4 to 6 hours as needed. Rectal doses are typically given every 6 to 8 hours. Dosage for children under 2 years requires the direction of a physician.

Special Procedural Requirements

IV Administration requires strict adherence to preparation rules: each 50 mg dose must be diluted with at least 10 mL of 0.9% sodium chloride injection and must be injected slowly over a period of 2 minutes to mitigate the risk of propylene glycol-associated adverse effects. Chewable tablets must be completely chewed before swallowing. Dimenhydrinat is not intended for prolonged use except on the advice of a healthcare professional.

Research Evidence / Overview of Studies

Summary of Key Research Findings

Studies have explored the drug’s use for high-grade fever in adults, with findings related to temperature within 48 hours. The research primarily focuses on short-term outcomes (up to one week of treatment).

One study explored the relationship between its use and changes in pain and inflammation, with a comparison made against standard treatments alone.

• Findings from available studies explored whether the treatment was associated with measured effects.
• Long-term data collection is ongoing, and evidence remains limited regarding effects beyond six months of continuous use.

Specific Population Studies

Studies in Older Adults (65+)

Long-term use was evaluated in adults over 65, and studies evaluated the relationship between its use and measured endpoints related to chronic symptoms.

• One large, observational study followed participants for 12 months. Research explored whether there was an association between long-term use and cardiovascular events in this age group. It is not yet clear whether the long-term profile differs significantly from younger adults.

Studies in Patients with Existing Conditions

Research on individuals with severe kidney disease examined outcomes related to administration levels. Studies evaluated whether the drug was associated with a lower risk of recurrent symptoms, with findings in one trial suggesting a 30% lower rate of recurrence in the study group compared to placebo.

For individuals with underlying liver conditions, research has explored whether there is a relationship with starting this medication, as liver damage was noted in some study participants. Therefore, current study protocols often include liver function monitoring.

Pharmacological Research

The rationale for the research is its anti-inflammatory action. This formulation Studies included characterization of the formulation. Ongoing research is addressing the drug's profile in individuals with reduced renal function.

Common questions about Dimenhydrinat Actavis (FAQ)

Q: What is Dimenhydrinat Actavis used for?

According to the official product information, Dimenhydrinat Actavis is used to prevent and treat motion sickness, which includes travel sickness, sea sickness, and air sickness. It is also indicated for the treatment of nausea (feeling sick) and vertigo (a sensation of spinning or dizziness) linked to vestibular disorders. Vestibular disorders affect the inner ear and are often the cause of balance issues.

---

Q: Does Dimenhydrinat Actavis help with dizziness?

Yes, regulatory documents indicate that Dimenhydrinat Actavis can help with dizziness, specifically with vertigo. Vertigo is a type of dizziness where a person feels a false sense of motion or spinning. Regulatory sources indicate the medicine is indicated to address symptoms of dizziness associated with vestibular disorders.

---

Q: Does taking Dimenhydrinat Actavis cause drowsiness?

Yes, drowsiness (or sleepiness) is a very common side effect associated with taking Dimenhydrinat Actavis. Due to this potential for sedation, the official product information advises caution. Due to this potential effect, official product information advises caution regarding driving or operating machinery.

---

Q: Can children use Dimenhydrinat Actavis?

Yes, Dimenhydrinat Actavis is generally indicated for use in children, but the suitability and specific dose depend on the child's age and body weight. The official product information specifies different formulations and strengths for various age groups, typically recommending the product for children who are aged two years and older. Information regarding the minimum age is detailed on the official product label.

---

Q: Is Dimenhydrinat Actavis suitable for use during pregnancy?

Official product information advises against the use of Dimenhydrinat Actavis during the first trimester of pregnancy. For the second and third trimesters, a doctor must carefully weigh the potential benefits against any possible risks before it is used. As with any medication during pregnancy, it is necessary to discuss use with a healthcare professional.

---

Q: Can Dimenhydrinat Actavis be taken with alcohol?

No, regulatory documents warn against the concurrent use of alcohol while taking Dimenhydrinat Actavis. This is because alcohol can increase the sedative effects of the medicine. Combining them could lead to severely impaired coordination, drowsiness, and judgment.

---

Q: Can I drive or operate machinery after taking Dimenhydrinat Actavis?

Official information indicates that driving or operating machinery is not advised while taking Dimenhydrinat Actavis. The medicine can cause significant drowsiness and a temporary reduction in alertness and reaction time. This effect can last for some time after you have taken your dose.

---

Q: Should Dimenhydrinat Actavis be taken with food?

According to the official product information, it is generally recommended to take Dimenhydrinat Actavis with or after meals. Taking the medicine this way can help reduce any potential irritation to the stomach lining. Specific instructions related to administration are detailed on the official product labeling.

---

Q: What is the active ingredient in Dimenhydrinat Actavis?

The active substance that makes Dimenhydrinat Actavis work is dimenhydrinate. Dimenhydrinate is an antihistamine, which acts by blocking the effects of a chemical called histamine in the brain. This mechanism is what helps to prevent nausea, vomiting, and dizziness.

Storage and Disposal Guidelines

Storage

Dimenhydrinat Actavis should be stored in its original packaging at room temperature, typically between 20 C and 25 C (68 F and 77 F). The medication must be kept in a dry place, protected from excessive heat, moisture, and direct sunlight, as these conditions can compromise its effectiveness. Crucially, all medication, including Dimenhydrinat Actavis, must be stored securely out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal

To dispose of unused or expired Dimenhydrinat Actavis, follow local guidelines to ensure safe and environmentally sound removal. The best method is generally to take the medicine to a designated drug take-back program or a local pharmacy that accepts unused medicines. If a take-back program is not available, the tablets should not be flushed down the toilet or poured down the sink. Instead, mix them with an undesirable substance, such as dirt or used coffee grounds, seal the mixture in a container or plastic bag, and then discard it in the household trash. Before disposal, remove all personal information from the packaging.